Review of Studies of Androgen Treatment of Female-to-Male Transsexuals: Effects and Risks of Administration of Androgens to Females
- 1 April 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 5 (4), 765-776
- https://doi.org/10.1111/j.1743-6109.2007.00646.x
Abstract
Testosterone supplementation in ovariectomized or elderly women may improve their sense of well-being and libido, muscle mass and strength, and bone mineral density. Naturally, androgens may have virilizing effects in women. It is often believed that androgens have deleterious effects on cardiovascular risks. To obtain an inventory of the effects of administration of testosterone on female biological functions. We reviewed here our publications on the effects of high-dose androgen administration to female-to-male transsexuals treated between 1975 and 2004 (N = 712). Annual accrual was at a steady rate of 22-30 persons. Dosages administered were far above those suited for women. There was special focus on the potential negative effects on cardiovascular risk markers. The standard treatment was administration of testosterone esters, 250 mg/2-3 weeks, parenterally). With this dose, virilizing effects on the skin and clitoris were prominent. Spatial ability improved, while verbal fluency deteriorated. The ovaries developed polycystic characteristics. Adequate dosages of testosterone preserved bone mass in females. Androgens increased kallikreins, such as prostate-specific antigen, in female reproductive tissues. High-dose testosterone administration appeared to increase weight, visceral fat, and hematocrit, decrease high-density lipoprotein cholesterol, increase endothelin-1, increase C-reactive protein, and increase total homocysteine. But blood pressure, insulin sensitivity, fibrinolytic markers, arterial stiffness, and levels of von Willebrand factor, fibrinogen, and interleukin-6 remained largely unchanged. Our studies demonstrated that, while some markers of cardiovascular risk factors showed a shift to a more negative risk profile, others were not affected. Androgen effects on cardiovascular risk markers are therefore not universally negative, and it is reasonable to assume that the latter effects will not be negative with the much lower doses suited for administration to women.This publication has 79 references indexed in Scilit:
- Long-Acting Intramuscular Testosterone Undecanoate for Treatment of Female-to-Male Transgender IndividualsThe Journal of Sexual Medicine, 2007
- Management of Female Sexual Dysfunction in Postmenopausal Women by Testosterone Administration: Safety Issues and ControversiesThe Journal of Sexual Medicine, 2007
- Ovarian Cancer Associated with Testosterone Supplementation in a Female-to-Male Transsexual PatientGynecologic and Obstetric Investigation, 2006
- Testosterone treatment comes of age: new options for hypogonadal menClinical Endocrinology, 2006
- Markers of hypercoagulability and inflammation predict mortality in patients with heart failureJournal of Thrombosis and Haemostasis, 2006
- Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male TranssexualsJournal of Histochemistry & Cytochemistry, 2006
- Androgen Replacement TherapyDrugs, 2004
- Influence of endogenous androgens on carotid wall in postmenopausal womenMenopause, 2001
- Effects of Androgens on Coronary Artery Atherosclerosis and Atherosclerosis-Related Impairment of Vascular ResponsivenessArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- The endocrinology of transsexualism: A review and commentaryPsychoneuroendocrinology, 1990